This article is more than 5 years old. Information may no longer be current.
iStent yields greatest IOP reduction in eyes with highest baseline pressure
FORT LAUDERDALE, Fla. — IOP reduction correlated strongly with preoperative IOP in patients who underwent cataract surgery with iStent implantation, according to a scientific poster presented at the American Glaucoma Society meeting here.
“The increased efficacy of the iStent among glaucoma patients with higher pressures means that those who need IOP reduction the most will experience the greatest benefit,” Reay H. Brown, MD, and colleagues wrote. “Longer follow-up shows that patients with IOP greater than 21 mm Hg have a substantial IOP reduction that persisted to almost 2 years. Patients with lower pressures can often have medications eliminated and continue to maintain a normal IOP.”
The study included 46 eyes that underwent cataract surgery with implantation of an iStent (Glaukos). Mean follow-up was 22 months.
Mean IOP reduction in the study eyes was 2.1 mm Hg (P < .001).
IOP was reduced in 71% of all patients, 100% of patients with the highest baseline IOP, and 91% of patients with baseline IOP of 18 mm Hg to 21 mm Hg.
Average medication reduction was 0.38 in patients with baseline IOP lower than 15 mm Hg, 0.63 in patients with baseline IOP between 15 mm Hg and 18 mm Hg, 0.36 in patients with baseline IOP between 18 mm Hg and 21 mm Hg, and 0.45 in patients with baseline IOP higher than 21 mm Hg. – by Matt Hasson and Patricia Nale, ELS
Disclosure: Brown reports he has financial relationships with Glaukos, Rhein, Ivantis and Transcend.